WHO. World health statistics 2023: monitoring health for the SDGs, sustainable development goals. 2023; :

P. Scheltens, B. De Strooper, M. Kivipelto, H. Holstege, G. Chételat, C. E. Teunissen. Alzheimer’s disease. Lancet 2021; 397(10284): 1577-1590.

M. Garcia-Alloza, F. J. Gil-Bea, M. Diez-Ariza, C. P. Chen, P. T. Francis, B. Lasheras. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia 2005; 43(3): 442-449.

S. Gauthier, C. Webster, S. Servaes, J. A. Morais, P. Rosa-Neto. Alzheimer’s Disease International: World Alzheimer Report 2022 – Life after diagnosis. 2022; :

B. Shal, W. Ding, H. Ali, Y. S. Kim, S. Khan. Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer’s disease. Front Pharmacol 2018; 9: 548.

J. W. Kinney, S. M. Bemiller, A. S. Murtishaw, A. M. Leisgang, A. M. Salazar, B. T. Lamb. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y) 2018; 4(1): 575-590.

H. Chen, Y. Zeng, D. Wang, Y. Li, J. Xing, Y. Zeng. Neuroinflammation of microglial regulation in Alzheimer’s disease. Molecules 2024; 29(7): 1338383.

S. Zhang, Z. Gao, L. Feng, M. Li, Y. Zhao, H. Huang. Prevention and treatment strategies for Alzheimer’s disease: focusing on microglia and astrocytes in neuroinflammation. J Inflamm Res 2024; 17: 7235-7259.

M. T. Heneka, D. T. Golenbock, E. Latz. Innate immunity in Alzheimer’s disease. Nat Immunol 2015; 16(3): 229-236.

F. L. Heppner, R. M. Ransohoff, B. Becher. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015; 16(6): 358-372.

S. A. Liddelow, K. A. Guttenplan, L. E. Clarke, F. C. Bennett, C. J. Bohlen, L. Schirmer. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017; 541(7638): 481-487.

R. X. Dou, Y. M. Zhang, X. J. Hu, F. L. Gao, L. L. Zhang, Y. H. Liang. Aβ1-42 promotes microglial activation and apoptosis in the progression of AD by binding to TLR4. Redox Biol 2024; 78: 103428.

X. Zhu, C. A. Rottkamp, A. Hartzler, Z. Sun, A. Takeda, H. Boux. Activation of MKK6, an upstream activator of p38, in Alzheimer’s disease. J Neurochem 2001; 79(2): 311-318.

M. T. Heneka, M. P. Kummer, A. Stutz, A. Delekate, S. Schwartz, A. Vieira-Saecker. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 2013; 493(7434): 674-678.

M. Jain, M. K. Singh, H. Shyam, A. Mishra, S. Kumar, A. Kumar. Role of JAK/STAT in neuroinflammation and its association with neurological disorders. Ann Neurosci 2021; 28(3-4): 191-200.

D. A. Butterfield, A. M. Swomley, R. Sultana. Oxidative stress in Alzheimer disease: role of Aβ peptide and mitochondrial dysfunction. Free Radic Biol Med 2013; 62: 157-169.

M. Gratuze, C. E. Leyns, D. M. Holtzman. New insights into the role of TREM2 in Alzheimer’s disease. Mol Neurodegener 2018; 13(1): 66.

L. Zhong, Y. Xu, R. Zhuo, T. Wang, K. Wang, R. Huang. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model. Nat Commun 2019; 10(1): 1365.

A. McQuade, M. Blurton-Jones. Microglia in Alzheimer’s disease: exploring how genetics and phenotype influence risk. J Mol Biol 2019; 431(9): 1805-1817.

T. R. Jay, C. M. Miller, P. J. Cheng, L. C. Graham, S. Bemiller, M. L. Broihier. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med 2015; 212(3): 287-295.

J. M. Taylor, M. R. Minter, A. G. Newman, M. Zhang, P. A. Adlard, P. J. Crack. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer’s disease. Neurobiol Aging 2014; 35(5): 1012-1023.

E. R. Roy, B. Wang, Y. W. Wan, G. Chiu, A. Cole, Z. Yin. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest 2020; 130(4): 1912-1930.

A. Abdullah, M. Zhang, T. Frugier, S. Bedoui, J. M. Taylor, P. J. Crack. STING-mediated type-I interferons contribute to the neuroinflammatory process and detrimental effects following traumatic brain injury. J Neuroinflammation 2018; 15(1): 323.

A. Nazmi, R. H. Field, E. W. Griffin, O. Haugh, E. Hennessy, D. Cox. Chronic neurodegeneration induces type I interferon synthesis via STING, shaping microglial phenotype and accelerating disease progression. Glia 2019; 67(7): 1254-1276.

Y. Shi, K. Yamada, S. A. Liddelow. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 2017; 549(7673): 523-527.

A. Grubman, G. Chew, J. F. Ouyang. Transcriptional signature in microglia associated with Aβ plaque phagocytosis. Nat Commun 2020; 11(1): 3016.

S. Krasemann, C. Madore, R. Cialic. The TREM2–APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 2017; 47(3): 566-581.

C. Venegas, S. Kumar, B. S. Franklin. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature 2017; 552(7685): 355-361.

S. Walter, M. Letiembre, Y. Liu. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem 2007; 20(6): 947-956.

C. A. Szekely, P. P. Zandi. Non-steroidal anti-inflammatory drugs and Alzheimer’s disease: the epidemiological evidence. CNS Neurol Disord Drug Targets 2010; 9(2): 132-139.

M. Miguel-Álvarez, A. Santos-Lozano, F. Sanchis-Gomar. Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer’s disease: a systematic review and meta-analysis of treatment effect. Drugs Aging 2015; 32(2): 139-147.

J. Cummings, G. Lee, A. Ritter. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019; 5(1): 272-293.

B. K. Martin, C. Szekely, J. Brandt. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65(7): 896-905.

P. S. Aisen, K. A. Schafer, M. Grundman. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289(21): 2819-2826.

A. Olmos-Alonso, S. T. Schetters, S. Sri. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain 2016; 139(Pt 3): 891-907.

E. Y. A. Qaid, Z. Abdullah, R. Zakaria. Minocycline ameliorates LPS-induced learning and memory impairment by inhibiting microglia and astrocyte activation in the hippocampus. IIUM Med J Malaysia 2022; 21(4): 53-59.

W. M. Song, S. Joshita, Y. Zhou. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 2018; 215(3): 745-760.

P. Mecocci, M. C. Polidori. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta 2012; 1822(5): 631-638.

P. H. Reddy, M. Manczak, X. Yin. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer’s disease. J Investig Med 2016; 64(8): 1220-1234.

J. M. Ringman, S. A. Frautschy, E. Teng. Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 2012; 4(5): 43.

M. D. Knutson, C. Leeuwenburgh. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 2008; 66(10): 591-596.

C. Sawda, C. Moussa, R. S. Turner. Resveratrol for Alzheimer’s disease. Ann N Y Acad Sci 2017; 1403(1): 142-149.

C. C. Chiu, K. P. Su, T. C. Cheng. The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(6): 1538-1544.

J. M. Ringman, S. A. Frautschy, G. M. Cole. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res 2005; 2(2): 131-136.

K. H. Cox, A. Pipingas, A. B. Scholey. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol 2015; 29(5): 642-651.